Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study

INTRODUCTION: Approximately 20–33% of all cancer patients are treated with acid-reducing agents (ARAs), most commonly proton pump inhibitors (PPIs), to reduce gastroesophageal reflux disease symptoms. Palbociclib and ribociclib are weak bases so their solubility depends on different pH. The solubili...

Descripción completa

Detalles Bibliográficos
Autores principales: Eser, Kadir, Önder, Arif Hakan, Sezer, Emel, Çil, Timuçin, İnal, Ali, Öztürk, Banu, Erçolak, Vehbi, Duman, Berna Bozkurt, Çelik, Halil, Köşeci, Tolga, Kesen, Oğuzhan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9078089/
https://www.ncbi.nlm.nih.gov/pubmed/35525929
http://dx.doi.org/10.1186/s12885-022-09624-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9078089/
https://www.ncbi.nlm.nih.gov/pubmed/35525929
http://dx.doi.org/10.1186/s12885-022-09624-y

Ejemplares similares